Rehabilitation plus OnabotulinumtoxinA Improves Motor Function over OnabotulinumtoxinA Alone in Post-Stroke Upper Limb Spasticity: A Single-Blind, Randomized Trial

• Published in: Toxins Vol. 9; no. 7; p. 216
• Main Authors: Devier, Deidre, Harnar, JoAnn, Lopez, Leandro, Brashear, Allison, Graham, Glenn
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI 11.07.2017; MDPI AG
• Subjects: Acetylcholine Release Inhibitors - therapeutic use; Aged; Botulinum Toxins, Type A - therapeutic use; Combined Modality Therapy; Female; Humans; Male; Middle Aged; muscle spasticity; Muscle Spasticity - drug therapy; Muscle Spasticity - etiology; Muscle Spasticity - physiopathology; Muscle Spasticity - rehabilitation; occupational therapy; onabotulinumtoxinA; physical therapy; rehabilitation; Single-Blind Method; stroke; Stroke - complications; Upper Extremity - physiopathology; muscle spasticity; rehabilitation; physical therapy; onabotulinumtoxinA; stroke; occupational therapy
• ISSN: 2072-6651; 2072-6651
• DOI: 10.3390/toxins9070216

OnabotulinumtoxinA (BoNT-A) can temporarily decrease spasticity following stroke, but whether there is an associated improvement in upper limb function is less clear. This study measured the benefit of adding weekly rehabilitation to a background of BoNT-A treatments for chronic upper limb spasticity following stroke. This was a multi-center clinical trial. Thirty-one patients with post-stroke upper limb spasticity were treated with BoNT-A. They were then randomly assigned to 24 weeks of weekly upper limb rehabilitation or no rehabilitation. They were injected up to two times, and followed for 24 weeks. The primary outcome was change in the Fugl-Meyer upper extremity score, which measures motor function, sensation, range of motion, coordination, and speed. The 'rehab' group significantly improved on the Fugl-Meyer upper extremity score (Visit 1 = 60, Visit 5 = 67) while the 'no rehab' group did not improve (Visit 1 = 59, Visit 5 = 59; = 0.006). This improvement was largely driven by the upper extremity "movement" subscale, which showed that the 'rehab' group was improving (Visit 1 = 33, Visit 5 = 37) while the 'no rehab' group remained virtually unchanged (Visit 1 = 34, Visit 5 = 33; = 0.034). Following injection of BoNT-A, adding a program of rehabilitation improved motor recovery compared to an injected group with no rehabilitation.